![]() Marker Therapeutics Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. | ![]() Amolyt Pharma Amolyt Pharma (formerly known as Alizé Pharma) is a company that specializes in the development of biopharmaceutical drugs, proteins, and peptides for the treatment of metabolic diseases and cancer. | ![]() Tosk Tosk is a biopharmaceutical company that provides drug development solutions for cancer treatment. | ![]() Bionomics Bionomics is a clinical-stage biopharmaceutical company developing ion channels targeting drug candidates designed for patients suffering from central nervous system (CNS) disorders. | |
Founding Date | Founding Date 2018 | Founding Date 2015 | Founding Date 2008 | Founding Date 1996 |
Type | Type Public | Type Subsidiary | Type Private | Type Subsidiary |
Tags | ||||
Locations | Locations Houston, US HQ | Locations Écully, FR HQ Cambridge, US | Locations Mountain View, US HQ Sunnyvale, US | Locations Eastwood, AU HQ |
Employees | Employees 888% decrease | Employees 373% decrease | Employees 109% decrease | Employees 7 |
Financial | ||||
Revenue (est.) | Revenue (est.) $3.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $264k (FY, 2022) |
Net income | Net income ($12.2m) (FY, 2025) | Net income N/A | Net income N/A | Net income ($21.8m) (FY, 2022) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 93.1m | Total funding raised $ 8.6m | Total funding raised $ 10.4m |

Amolyt Pharma (formerly known as Alizé Pharma) is a company that specializes in the development of biopharmaceutical drugs, proteins, and peptides for the treatment of metabolic diseases and cancer.
View company
Tosk is a biopharmaceutical company that provides drug development solutions for cancer treatment.
View company
Bionomics is a clinical-stage biopharmaceutical company developing ion channels targeting drug candidates designed for patients suffering from central nervous system (CNS) disorders.
View company